Deferred and Contingent Consideration Liabilities 2018 2017 m m Deferred consideration less than one year 1.8 Deferred consideration more than one year 2.3 1.8 2.3 Contingent consideration less than one year 7.0 1.6 Contingent consideration more than one year 28.0 31.1 35.0 32.7 36.8 35.0 The consideration for certain acquisitions and licensing agreements includes amounts contingent on future events such as development milestones or sales performance.
The Group has provided for the fair value of this contingent consideration as follows: StrixNB & Injectable Tri-Solfen DispersinB Solution Phycox Other Total As at 1 July 2016 3.0 0.6 3.6 Additions 26.4 3.6 30.0 Cash payments: investing activities 0.5 0.5 Finance expense 0.5 0.1 0.4 Foreign exchange adjustments 0.9 0.1 0.8 At 30 June 2017 25.5 3.6 3.1 0.5 32.7 Additions 6.5 2.4 8.9 Remeasurement through intangibles 0.9 2.2 3.1 Remeasurement through income statement 0.1 0.1 Cash payments: investing activities 0.6 1.1 1.7 Finance expense 0.4 0.2 0.6 Foreign exchange adjustments 1.8 0.2 0.1 0.1 2.0 Other movements 0.3 0.3 At 30 June 2018 22.8 1.1 6.6 2.8 1.7 35.0 The consideration payable for Tri-Solfen is expected to be payable over a number of years, and relates to development milestones and sales performance.
During the year, the development milestones have been remeasured and consequently are now expected to happen later than initially anticipated.
The consideration payable for StrixNB and Dispersin B is expected to be payable over a number of years, and relates to developments milestones and sales performance.
During the year the contingent consideration has been remeasured and consequently one of the development milestones is no longer expected to be achieved.
To the extent possible this has been remeasured through intangibles with the excess being credited to the income statement, and treated as non-underlying.
The consideration for a new licensing agreement for an injectable solution relates to development milestones, and Phycox relates to sales performance.
Where a liability is expected to be payable over a number of years the total estimated liability are discounted to their present values.
Related Party Transactions Subsidiaries The Groups ultimate Parent Company is Dechra Pharmaceuticals PLC.
A listing of subsidiaries is shown within the financial statements of the Company on pages 163 and 164.
Transactions with Key Management Personnel The details of the remuneration, Long Term Incentive Plans, shareholdings, share options and pension entitlements of individual Directors are included in the Directors Remuneration Report on pages 83 to 98.
The remuneration of key management is disclosed in note 8.
Non-Controlling Interests Refer to note 27 for transactions with non-controlling interests during the year.
Off Balance Sheet Arrangements The Group has no off balance sheet arrangements to disclose as required by S410A of the Companies Act 2006.
